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Abstract
Background: Rhino-orbito-cerebral mucormycosis(ROCM) is an invasive fungal infection that usually occurs in
immunocompromised patients and sometimes presents as orbital apex syndrome(OAS) initially. It is rapidly fatal
without an early diagnosis and treatment. We report the cases of invasive ROCM presenting with OAS initially in
order to raise the attention of clinicians.
Methods: We retrospectively investigated eleven cases of invasive ROCM presenting initially with OAS admitted
between January 2006 and December 2013. We analyzed clinical features, results of laboratory and radiological
examinations, nasal endoscopy, aggressive surgical excision and debridement, and medical management outcomes
of each case.
Results: A total of eleven cases of invasive ROCM with OAS as an initial sign were presented. Mucormycosis was
accompanied by type II diabetes mellitus in nine cases, renal transplant in one case, and injury caused by traffic
accident in one case. Anterior rhinoscopy revealed palatine or nasal necrotic lesions in all patients, and
transethmoidal optic nerve decompression was carried out in three patients at the same time. CT scan revealed
rhino-orbital-cerebral involvement in every patient. All patients were given intravenous amphotericin B. Nine
patients underwent surgical debridement of necrotic tissue. Three patients survived.
Conclusions: ROCM is a severe, emergent and fatal infection requiring multidisciplinary management. It may often
present with OAS initially. For ophthalmologist, mucormycosis must be considered in immunocompromised
patients presenting with OAS initially, and anterior rhinoscopy is imperative before hormonotherapy, even in the
cases absent of ketoacidosis induced by diabetes mellitus.
Keywords: Rhino-orbito-cerebral mucormycosis, Orbital apex syndrome, Ocular manifestations, Diabetes mellitus,
Immunocompromise
Background
Mucormycosis is a rare and severe opportunistic fungal
infection resulted from a fungus of the order mucorales. At
present, the incidence of fungal infections is increasing.
Mucormycosis is the second most frequent fungal infection
following aspergillus [1–3]. This fungal infection can rap-
idly progress in individuals who are immunologically or
metabolically compromised through vascular thrombosis or
central nervous system involvement [4]. The most common
co-morbidities include diabetes mellitus, lymphoid malig-
nancy, burn, severe trauma, renal failure and steroid thera-
phy [5, 6].
The rhino-orbital-cerebral presentation is the most
frequent. The diagnosis is often made late and relies on
anatomopathological and mycological examinations, espe-
cially for some patients presenting with atypical symptoms
initially for example swelling lid, nasal stuffiness, vision loss
et al. Rhino-orbital-cerebral mucormycosis (ROCM) may
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Early diagnosis and appropriate medical management are
vital to save the life. In this paper, we retrospectively
presented eleven cases of ROCM with ocular symptoms
initially and discussed clinical features, results of laboratory
investigations, radiological examinations and treatment
outcomes of each case.
Methods
Eleven ROCM patients with orbital apex syndrome(OAS)
initially presenting to our hospital between January 2006
and December 2013 were retrospectively investigated.
These studies were conducted in full conformance with the
principles of the Declaration of Helsinki in 1995 or with the
laws of China, which ever afforded the greater protection to
the study participant. Written informed consents were
obtained from the Institutional Research Ethics Committee
at the Affiliated Hospital of Qingdao University and eleven
patients for publication of this research article and any
accompanying images.
Evaluation at presentation included a detailed history,
clinical signs, ENT, ophthalmic, and neurological exam-
ination to assess the extent of disease, nasal endoscopy
with biopsy, and results of laboratory and radiological
examinations.
The diagnosis of mucormycosis was made by histological
examination of biopsy samples and finding filaments of the
Mucorales order. CT and MRI scan revealed rhino-orbital-
cerebral involvement in every patient. Treatment with
systemic amphotericin B was started as soon as the diagno-
sis of mucormycosis was established. Treatment was also
instituted to stabilize the underlying metabolic derange-
ment and surgical debridement was indicated.
Results
Out of 11 cases of ROCM followed and treated in our
hospital, three were female and eight were male. The
mean age of the patients was 53.7 years (range: 45–60
years). Diabetes was the most frequent risk factor, pre-
senting in nine patients. One patient presented with
renal transplant, and one was injured by traffic accident
.Of 11 cases of mucormycosis with rhino-orbito-cerebral
involvement, all had OAS. Vision was altered in all
patients including blindness in eight and only perception
of light/hand moving in three cases.
The main clinical signs on physical examination were
progressively decreased vision (n = 11), involvement of
cranial nerves (n = 11), blepharoptosis (n = 11), exoph-
thalmia (n = 9), periorbital edema (n = 9), and facial
swelling (n = 8) (Fig. 1).
Table 1 shows main clinical features, locations of the
involvements, imaging manifestation, and therapeutic
data of the cases.
Table 2 shows clinical signs and symptoms of the cases
of mucormycosis.
All the patients underwent CT/MRI scan of the parana-
sal sinuses, orbit and craniocerebrum. Pansinusitis was
found in eight patients, and maxilloethmoidal sinusitis
was found in three patients. The thickening sinus mucosa
and extension of lesions to the orbits were observed in all
patients. Four patients presented with thrombosis of
cavernous sinuses. Extensionto frontal lobes, dilatation of
the ventricular system and cortical grooves, and thrombo-
phlebitis of the right lateral sinus were observed in one
patient each. MRI performed in one patient revealed le-
sion predominantly located in sphenoid sinus, involving
the left orbital apex (Fig. 2).
On anterior rhinoscopy all patients had black blood
stained debris in the region of inferior and middle turbin-
ate along with necrosis on endoscopy. Direct examination
was performed after PAS staining. Tissue specimens for
culture were obtained from all cases. The culture was
made on Sabouraud chloramphenicol medium with and
without cycloheximide. In ten cases, the diagnosis of
mucormycosis was based on positive histopathological
findings for mucormycosis (Fig. 3). In three cases, Mucor
spp. was isolated from tissue cultures and it was patho-
logically verified in all patients of mucormycosis. The
histological examination revealed large non-septate myce-
lial filaments, sometimes branched at a right angle with
images of angioinvasion within necrotic and inflammatory
material.
Duration of illness between the first clinical signs and
diagnosis ranged from 10 days to 50 days. At the early
stage, the nasal and sinus phase was neglected by all
patients. Once diagnosis, all patients had received antifun-
gal treatment with amphotericin B, at 0.3 mg/kg per day
initially with close renal function monitoring, gradually up
to maximum dose at 1 mg/kg per day for an average of 4–6
weeks. During the course, three patients presented with
severe renal insufficiency induced by amphotericin B treat-
ment leading to treatment interruption and switched to
itraconazole. For the patients accompanied with diabetes
mellitus or renal transplantation, insulin therapy with a
strict surveillance of glycemia or the therapy with improve-
ment of renal function was prescribed. Meanwhile, nine
cases received surgical debridement of necrotic tissue asso-
ciated to drug therapy.
Finally, one patient with trauma had been rapidly trans-
ferred to the ICU for severe skin and soft tissue infection,
and died of septicemia and acute respiratory insufficiency.
The patient with renal transplantation refused further
treatment and died of renal failure. The outcome was
favorable for three patients with diabetes mellitus, 12, 18,
and 24 months later, respectively. Three patients had
fulminating disease and early mortality due to intracranial
and pulmonary infection. One died of ventricular
arrhythmia disorder, one died of neurological distress, and
one case was due to hemorrhagic shock.
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Discussion
Mucormycosis is a rare filamentous and fatal fungal infec-
tion mostly encountered among immuno-suppressed pa-
tients [7, 8]. The most common risk factors accompanied
with mucormycosis are diabetes mellitus, especially ketoa-
cidosis, immunosuppressive conditions like hematologic
malignancies and organ transplantations [9–11]. Nine
patients (81.8 %) had diabetes mellitus, in which neutro-
phils had an impaired ability of phagocytosis and chemo-
taxis [12]. Presence of diabetic ketoacidosis increases
predisposition to mucormycosis. Acidosis disrupts iron
binding of transferrin, resulting in increased proportion of
unbound iron, which may promote growth of the fungus
[13, 14]. Another accompanying disease is renal trans-
plantation. The least frequently accompanying disease is
haematological malignity.
Mucormycosis presents in various distinct forms
depending on the immunological status of the host
and the affected site. Among the various localizations,
the rhino-orbital-cerebral presentation is the most fre-
quent (40 %) [15, 16]. The fungus invades the wall of
the blood vessels, causing mechanical and toxic dam-
age to the intima leading to thrombosis, and later it
invades the lymphatics and veins. These thromboses
cause emboli and vascular obstruction responsible for
tissue necrosis.
The infection progressively spreads from the nasal
mucosa to the nose, facial sinuses, the palate, orbits
and brain. It evolves in three stages: nasal and sinus in-
volvement often pauci or asymptomatic unnoticed by
the patient, orbital involvement motivating the patient
for consultation, and finally cerebral involvement.
OAS is a rare syndrome with retro-orbital pain,
complete ophthalmoplegia, and visual loss. In the eti-
ology of OAS, inflammatory, infectious, neoplastic,
iatrogenic/traumatic and vascular pathologies should
Fig. 1 Pre-operative aspect of patient exhibiting bilateral periorbital edema with facial swelling, exophthalmia, blepharoptosis,and Ocular
purulent secretion
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be considered [17]. Fungal infections can cause exten-
sive tissue damage potentially leading to permanent
vision loss and death if not treated [18]. Species of
Fusarium, Aspergillus, Candida, dematiaceous fungi,
Mucorales and Scedosporium predominate. Diagnosis
is aided by recognition of typical clinical features and
by direct microscopic detection of fungi in scrapes,
biopsy specimens, and other samples. Culture con-
firms the diagnosis. Histopathological, immunohisto-
chemical, or DNA-based tests may also be needed
[19]. For example, ROCM, also known as mucormy-
cosis, is commonly caused by the non-septate fila-
mentous fungus, Rhizopus oryzae [20]. Patients with
ROCM present acutely and progress rapidly. Another
fungal orbital infection important to understand is
sino-orbital aspergillosis. Sino-orbital Aspergillus in-
fection can occur acutely or chronically and can affect
both the immunocompetent and immunocomprom-
ised [21, 22]. Invasive Aspergillus infection in the
immunocompetent host usually presents in a more
indolent but progressive course. CT imaging can
show heterogenous soft tissue enhancement with focal
bony destruction with intraluminal calcification being
indicative of an Aspergillus infection [23, 24].
For mucormycosis with a late diagnosis, the evolution
is marked by extension to the orbits. The orbital in-
volvement is related to the vascular tropism of the fun-
gus inducing arteriole thrombosis affecting the orbit
wall, oculomotor and optical nerves responsible for
blindness with or without thrombosis of the ophthalmic
artery. It is unilateral and marked by orbital pain, diplo-
pia, ophthalmoplegia, periorbital edema, chemosis,
exophthalmia or even blindness. OAS may be firstly
diagnosed. Eye fundus is a key examination for the
diagnosis of ROCM. It may reveal a venous congestion
or thrombosis of the artery or of the central vein of
retina, optic atrophy or panophthalmia [16, 25–27]. In
the OAS, the prognosis is good if treated early. There is
mucosal invasion and hence radical debridement and
antifungal therapy is imperative. If the inflammation
can’t be controlled, intracranial involvement occurs
from invasion by way of superior orbital fissure, oph-
thalmic vessels, cribriform plate and not uncommonly,
through carotid artery.
In the patients involved in our study, the clinical
signs and symptoms of mucormycosis may vary with
the involved organ widely. Mostly, the clinical presen-
tation is atypical. Nasal discharge or nasal blockage
may occur in a small proportion of the patients.
Sometimes even eschar, typical presentation of rino-
cerebral mucormycosis may not appear. The patients
reported here most frequently presented with ptosis,
exophthalmia and examination of the revealed sinuses
Table 1 main clinical features, locations of the involvements,
imaging manifestation, and therapeutic data of the cases
N
Cases 11











Orbital apex syndrome 11
Imaging manifestation(CT/MRI)
Thickening in sinus Mucosa 11
Inflammation in the periorbital muscles 11
Involvement of the cavernous sinus 4
Occlusion of the internal carotid artery 2






Survive with sequeale 3
Death 8






Cranial nerve palsy 11 100




Periorbital edema 9 81.8
Facial swelling and pain 8 72.7
Ocular purulent secretion 7 63.6
Nasal blockage/crusting 6 54.5
Blood stained discharge 5 45.5
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eschar in most of cases. In such patients, MRI has
the advantage of detecting early vascular and intracra-
nial invasion.
Successful treatment of mucormycosis is based on
three principles. First, early diagnosis is greatly im-
perative and can enormously reduce the patient’s mor-
tality. Second, necrotic tissues should be aggressively
debrided or infected tissues should be resected. Last,
medical treatment with antimycotic agents should be
carried out [7]. Surgical therapy alone has a great
influence on treatment outcome in cases of mucormy-
cosis. In fact, Tedder et al. reported that the mortality
rate was 11 % in patients who underwent surgery but
60 % in patients without surgical therapy [28]. Sys-
temic antifungal therapy includes the use of high dose
amphotericin B and is associated with an overall
survival rate of 72 %. It is usually given in dextrose
5 % in water intravenously at a dose of 1.0–1.5 mg/kg
daily since its usage is associated with renal toxicity
and it requires careful monitoring of serum urea nitro-
gen, blood urea nitrogen, potassium, creatinine as well
as creatinine clearance as an essential part of the ther-
apy. Recently, studies have shown that liposomal
amphotericin B and fluconazole, caspofungin can be
combined with each other. Hyperbaric oxygen therapy
is believed to improve neutrophilic killing by higher
oxygen delivery, low dose of heparin, anti inflamma-
tory medicine can be used with good success [29–31].
Prognosis is dependent on multiple factors and early
initiation of treatment is an important element. A multi-
disciplinary approach consisting of dental specialists, ENT
surgeons, ophthalmologists and neurologist is critical in
Fig. 2 MRI presentations of mucormycosis presented with orbital apex syndrome. a: Axial T1WI MR shows a isointensity lesion in the left orbital
apex;b: Axial T2WI MR shows a hypointensity lesion in the left orbital apex and high signal in the sphenoid sinus; c: Axial contrast-enhanced T1WI
MR shows a enhancing lesion in the left orbital apex; d: Coronal contrast-enhanced T1WI MR shows a enhancing lesion in the left orbital apex
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successful management of a patient with mucormycosis.
Hence the general approach is to treat early, aggressively
and with all modalities available.
Conclusions
Mucormycosis is a severe, emergent and fatal infection
requiring multidisciplinary management. It is a disease
with various presentations, and sometimes its manifes-
tations are atypical. For ophthalmologist, it should be
kept in mind when dealing with the case of OAS, even
exophthalmia, progressive periorbital or facial edema or
necrosis, with or without involvement of cranial nerves
in the patients accompanied with immunodeficiency
disorders. The diagnosis relies on histological and
mycological examination data. Early diagnosis and ur-
gent antifungal treatment associated to surgery are of
extreme importance for successful eradication of infec-
tion and for patient survival.
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